BR9710030A - Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] - Google Patents

Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]

Info

Publication number
BR9710030A
BR9710030A BR9710030A BR9710030A BR9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A BR 9710030 A BR9710030 A BR 9710030A
Authority
BR
Brazil
Prior art keywords
bis
recombinant adenoviruses
propanottl
didroxypropyl
benzenocarboxamide
Prior art date
Application number
BR9710030A
Other languages
English (en)
Inventor
Francis Blanches
Jean-Marc Guillaume
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9608164A external-priority patent/FR2750433B1/fr
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9710030A publication Critical patent/BR9710030A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9710030A 1996-07-01 1997-06-20 Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] BR9710030A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9608164A FR2750433B1 (fr) 1996-07-01 1996-07-01 Procede de production d'adenovirus recombinants
US2666796P 1996-09-25 1996-09-25
PCT/FR1997/001107 WO1998000524A1 (fr) 1996-07-01 1997-06-20 Procede de production d'adenovirus recombinants

Publications (1)

Publication Number Publication Date
BR9710030A true BR9710030A (pt) 1999-08-10

Family

ID=26232805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710030A BR9710030A (pt) 1996-07-01 1997-06-20 Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]

Country Status (13)

Country Link
US (3) US6485958B2 (pt)
EP (1) EP0944717A1 (pt)
JP (1) JP2000514290A (pt)
KR (1) KR20050043996A (pt)
AU (1) AU3447097A (pt)
BR (1) BR9710030A (pt)
CA (1) CA2258158A1 (pt)
CZ (1) CZ438398A3 (pt)
HU (1) HU224558B1 (pt)
IL (1) IL127692A0 (pt)
NO (1) NO986202L (pt)
SK (1) SK181098A3 (pt)
WO (1) WO1998000524A1 (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143548A (en) * 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
US6485958B2 (en) * 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
DE69739961D1 (de) 1996-12-13 2010-09-23 Schering Corp Methoden zur Virus-Reinigung
US6146891A (en) 1997-01-31 2000-11-14 Schering Corporation Methods for cultivating cells and propagating viruses
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
BR9909789A (pt) * 1998-04-22 2000-12-26 Genvec Inc Método de purificação eficiente de adenovìrus
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
AU770672B2 (en) * 1998-05-27 2004-02-26 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP2003523169A (ja) * 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー ウイルス粒子の分離法
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
US7264958B1 (en) 1999-02-22 2007-09-04 Transgene, S.A. Method for obtaining a purified viral preparation
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US7319002B2 (en) * 2001-08-08 2008-01-15 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
MXPA04006995A (es) * 2002-01-18 2005-07-13 Schering Ag Formulaciones estabilizadas de adenovirus.
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
CA2496918A1 (en) * 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US7078218B2 (en) * 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
DK1585812T3 (en) * 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
CA2518546C (en) * 2003-03-20 2012-11-13 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20040229335A1 (en) 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
WO2004112707A2 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
ATE432285T1 (de) * 2003-07-11 2009-06-15 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
ES2321212T3 (es) * 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
KR20070104339A (ko) * 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
WO2006057876A2 (en) * 2004-11-22 2006-06-01 Cedars-Sinai Medical Center Methods and solutions for tissue preservation
NZ561681A (en) 2005-03-21 2011-01-28 Virobay Inc Alpha ketoamide compounds as cysteine protease inhibitors
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
ATE518958T1 (de) 2007-01-30 2011-08-15 Transgene Sa Zur impfung verwendetes papillomavirus-e2- polypeptid
PL2183368T3 (pl) 2007-06-21 2016-12-30 Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
MX2011004292A (es) * 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
EP2461826A2 (en) 2009-08-07 2012-06-13 Transgene SA Composition for treating hbv infection
CN102791852B (zh) 2009-10-15 2014-05-07 克鲁塞尔荷兰公司 纯化腺病毒颗粒的方法
MX2012004221A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
JP2013523175A (ja) * 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
JP5940554B2 (ja) 2010-12-09 2016-06-29 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ 高収量の組換えタンパク質発現を得るためのｍｇｍｔに基づく方法
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013135615A1 (en) 2012-03-12 2013-09-19 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AU2013237424B2 (en) 2012-03-22 2017-07-06 Janssen Vaccines & Prevention B.V. Vaccine against RSV
SG11201408101TA (en) 2012-06-05 2015-01-29 Univ Australian Vaccination with interleukin-4 antagonists
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
SG11201506624SA (en) * 2013-02-28 2015-09-29 Psioxus Therapuetics Ltd A process for the production of adenovirus
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
GB201415579D0 (en) * 2014-09-03 2014-10-15 Psioxus Therapeutics Ltd A process
WO2015200897A2 (en) * 2014-06-27 2015-12-30 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
KR20170044194A (ko) * 2014-08-27 2017-04-24 싸이오서스 테라퓨틱스 엘티디. 아데노바이러스의 제조를 위한 공정
US9862936B2 (en) 2015-01-13 2018-01-09 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
EP3319633B1 (en) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Vaccine against rsv
BR112017028449A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv polipeptídeos rsv f pré-fusão solúveis estabilizados
WO2017147265A1 (en) * 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
AU2017272504A1 (en) 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
SG11201906271QA (en) 2017-02-09 2019-08-27 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes
CN110799529A (zh) 2017-04-22 2020-02-14 免疫治疗有限公司 改良lamp构建物
IL297073B2 (en) 2017-05-02 2023-12-01 Immunomic Therapeutics Inc LAMP constructs containing cancer antigens
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
JP2022521268A (ja) 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230029453A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JPH09508017A (ja) * 1994-01-12 1997-08-19 ジェネティック セラピー，インコーポレイテッド レトロウイルスベクターの精製
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
DK0751988T3 (da) * 1994-03-22 2000-06-26 Immune Response Corp Inc Højeffektiv fremstilling og isolering af virale partikler
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US6485958B2 (en) * 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
JP2003523169A (ja) * 1998-12-31 2003-08-05 アバンテイス・フアルマ・エス・アー ウイルス粒子の分離法

Also Published As

Publication number Publication date
AU3447097A (en) 1998-01-21
HU224558B1 (hu) 2005-10-28
NO986202L (no) 1999-02-15
JP2000514290A (ja) 2000-10-31
WO1998000524A1 (fr) 1998-01-08
HUP0001271A3 (en) 2002-01-28
EP0944717A1 (fr) 1999-09-29
SK181098A3 (en) 1999-07-12
IL127692A0 (en) 1999-10-28
HUP0001271A1 (hu) 2000-08-28
CA2258158A1 (fr) 1998-01-08
KR20050043996A (ko) 2005-05-11
CZ438398A3 (cs) 1999-03-17
NO986202D0 (no) 1998-12-30
US20050287657A1 (en) 2005-12-29
US6485958B2 (en) 2002-11-26
US20030143730A1 (en) 2003-07-31
US20020028497A1 (en) 2002-03-07
US6905862B2 (en) 2005-06-14

Similar Documents

Publication Publication Date Title
BR9710030A (pt) Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
LU91314I2 (fr) "Combinaison de particules viroides de papillomavirus humain de type 6, 11, 16 et 18 (GARDASIL -GilGARD )"
AR240251A1 (es) Metodo para preparar una composicion para tratamiento de infecciones virales y un metodo para sintetizar 3' azido 2', 3' dideoxiuridina destinada a la preparacion de dicha composicion.
DE69721840D1 (en) Zuckerrohr bacilliformviruspromotor
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
BR9205163A (pt) Processo para a preparacao de protease alcalina altamente purificada a partir de um caldo de fermentacao,composicao e protease alcalina purificada
DK0386734T3 (da) Immunogene regioner på E-7-proteinet af humant papillomavirus type 16
GB2287024B (en) Preparation and purification of L-5-(2-hydroxypropylamino)-2,4,6-triiodoisophthalic acid bis-(1,3-dihydroxypropylamide) contrast agent
WO1996029413A3 (en) Dna encoding human papilloma virus type 18
BR9708227A (pt) Processo de purificação de dna duplo filamento de pureza farmacêutica preparação de dna plasmídico recombinante e composição farmacêutica
BR9507771A (pt) Processos para preparação de ácido 1-Butil-2-(2'-(2H-Tetratozol-5-IL)-Bifenil-4-Ilmetil(-1H-Indol-3-Carboxílico
CA2200582A1 (en) Dna encoding human papillomavirus type 6a
FR2608159B1 (fr) Nouveaux derives de l'acide furannuronique, leur preparation et leur utilisation comme medicaments
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
BR9501546A (pt) Processo para a preparação de 2,2-difluorceteno silil O,S-acetais processo para preparar tioésteres de ácido alfa alfa-diflúor-beta-sililóxi-1,3-dioxolano-4-propanóico e 2,2-difluorceteno silil O,S-acetato obtido
IL120483A (en) Process for the preparation of (S)-N-N'-bis¬2-hydroxy-1-hydroxymethyl)ethyl¾-5-(2-acetoxy-propionylamino)-2,4,6-triiodo-isophthalamide
NO921580D0 (no) Soetningsmiddel utledet fra l-aspartinsyre og l-glutaminsyre og fremgansmaate ved fremstilling derav
FR2727111B1 (fr) Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
FR2601021B2 (fr) Fraction immunogene active a l'egard des bilharzioses, sa preparation, compositions immunisantes la contenant
IT1198230B (it) Procedimento per individuare la velocita' e i paramenti operativi ottimali di roccatura per ogni tipo di filato
AU7738896A (en) Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
IT1189070B (it) Processo per la preparazione della l(-)-carnitina cloruro a partire da esteri 3,4-epossibutirrici
FR2612186B1 (fr) Carbonyl 2,2' bis (alkyl-4 oxadiazolidines-1,2,4-diones-3,5), leur procede de preparation et leur utilisation comme intermediaires de synthese dans la preparation de carbamates
YU48589A (en) Process for improved preparation of4,4'-dinitro-stilbene-2,2'-disulphonic acid and it's salts
FR2603303B1 (fr) Procede de preparation de la carnitine par hydrolyse du carnitinamide, l'enzyme nouvelle utilisee dans ce procede et sa preparation

Legal Events

Date Code Title Description
TC Change of name
B25A Requested transfer of rights approved

Owner name: GENCELL S.A. (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: GENCELL S.A. (FR)

Free format text: A FIM DE ATENDER AO PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO NO 030277/RJ, DE 31/05/04, APRESENTE O DEVIDO DOCUMENTO DE ALTERACAO DE RAZAO SOCIAL.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GENCELL S.A. (FR)

Free format text: REFERENTE A RPI 1856 COD. (25.6) DE 01/08/2006, POR TER SIDO INDEVIDO.

B25D Requested change of name of applicant approved

Owner name: GENCELL SAS (FR)

Free format text: ALTERADO DE: GENCELL S.A.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO, ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.

B25D Requested change of name of applicant approved

Owner name: CENTELION S.A.S. (FR)

Free format text: ALTERADO DE: GENCELL SAS